Keywords2-benzopyrans; Sharpless Asymmetric Dihydroxylation; spirocycles; σ affinity; radiochemistry; positron emission tomography; autoradiography; organ distribution; EGFR; radiolabeled cetuximab conjugates; radioimmunotherapy (RIT); cancer theranostics; external beam radiotherapy (EBRT); endoradionuclide therapy; cannabinoid receptor type 2 ligand; CB2 receptor; neurodegeneration; radiolabeling; autoradiography; small-animal PET; terbium-149; alpha-therapy; folate receptor; DOTA-folate; KB tumors; 149Tb-cm09; albumin binder, radionuclide therapy; positron emitter; radiolabeling; nanoparticles; polymers; drug delivery; PET; imaging; nanomedicine; neurotensin receptor; positron emission tomography; radiotherapy; lutetium-177; RGD peptide; angiogenesis; PSMA; prostate-specific membrane antigen; PET; positron emission tomography; prostate cancer; DUPA; Ga-68; Y-90; Lu-177; radionuclide therapy; Kryptofix® 2.2.2; tetrabutylammonium; fluorine-18; quality control; thin layer chromatography (TLC) spot test; multifunctional radioconjugates; intra- and extracellular targeting; tumor-targeting; 99mTc-tricarbonyl; bombesin; shepherdin; gastrin releasing peptide receptor; Hsp90; SPECT; tracer; molecular probe; PET; radiopharmaceutical; 68Ga-PET imaging; PSMA; HBED-CC; prostate cancer; radiopharmaceutical production; good manufacturing practice; GMP; n/a
